Want to join the conversation?
$AGN's U.S. Brands net revenues for 1Q16 increased by 27% to $2.3Bil from last year. Growth was mainly attributed to the acquisition of legacy Allergan products. Net segment contribution for 1Q16 increased 33% over the prior year period to $1.5Bil primarily as a result of the Allergan acquisition.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.